[go: up one dir, main page]

SI9620076B - Stabilni reagenti za pripravo radiofarmacevtikov - Google Patents

Stabilni reagenti za pripravo radiofarmacevtikov Download PDF

Info

Publication number
SI9620076B
SI9620076B SI9620076A SI9620076A SI9620076B SI 9620076 B SI9620076 B SI 9620076B SI 9620076 A SI9620076 A SI 9620076A SI 9620076 A SI9620076 A SI 9620076A SI 9620076 B SI9620076 B SI 9620076B
Authority
SI
Slovenia
Prior art keywords
substituted
group
independently selected
occurrence
alkyl
Prior art date
Application number
SI9620076A
Other languages
English (en)
Other versions
SI9620076A (sl
Inventor
Michael Sworin
Milind Rajopadhye
Thomas David Harris
David Scott Edwards
Edward Hollister Cheesman
Shuang Liu
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of SI9620076A publication Critical patent/SI9620076A/sl
Publication of SI9620076B publication Critical patent/SI9620076B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (7)

  1. -1- STABILNI REAGENTI ZA PRIPRAVO RADIOFARMACEVTIKOV PATENTNI ZAHTEVKI 1. Reagent, ki ima formulo: (Q)d'Ln-Hz, in njegove farmacevtsko sprejemljive soli pri čemer, Q je biološko aktivna skupina, izbrana iz skupine: peptidov, polipeptidov in peptidomimetikov; d' je 1-20; Ln je povezovalna skupina s formulo: M1 -[Y1 (CR55R56)f(Z1 pri čemer M1 je •l(CH2)gZ1jg-(CR55R56)g~-; M2 je -(CR55RSVlZ1 (CH2)g]g-; g je neodvisno 0-10; g' je neodvisno 0-1; g" je neodvisno 0-10; f je neodvisno 0-10; -2- f' je neodvisno 0-10; f ‘ je neodvisno 0-1; Y1 in Υ2 sta ob vsakem pojavu neodvisno izbrana iz: c« 56 vezi, O, NR , C=0, 0(=0)0, 0C(=0)0, C(=0)NH-, C=NR , S, SO, S02, S03, NHC(=0), (NH)2C(=0), (NH)2C=S; Z1 je ob vsakem pojavu neodvisno izbran iz C6-C14 nasičenega, delno nasičenega, ali aromatskega karbocikličnega obročnega sistema, 57 substituiranega z 0-4 R ; in heterocikličnega obročnega sistema, 57 substituiranega z 0-4 R ; 55 56 R in R sta ob vsakem pojavu neodvisno izbrana iz: vodika; C^-C^q 57 alkila substituiranega z 0-5 R ; alkarila, pri čemer je aril substituiran z 0-5 R57; 57 58 R je ob vsakem pojavu neodvisno izbran iz skupine: vodika, OH, NHR , C(=0)R58, 0C(=0)R58, 0C(=0)0R58, C(=0)0R58, C(=0)NR58, C=N, SR58, SOR58, S02R58, NHC(=0)R58, NHC(=0)NHR58, 58 NHC(=S)NHR ; ali, alternativno, ko je vezan na dodatno molekulo Q, je 57 58 R ob vsakem pojavu neodvisno izbran iz skupine: O, NR , C=0, 0(=0)0, 00(=0)0, C(=0)N-, C=NR58, S, SO, S02, S03, NHC(=0), (NH)2C(=0), (NH)2C=S; in, 58 R je ob vsakem pojavu neodvisno izbran iz skupine: vodika; C1-C5 alkila; benzila, in fenila; Hz je stabilen hidrazon s formulo: R80 NsC R^-n' R81 V1 -3- pri čemer, 40 R je ob vsakem pojavu neodvisno izbran iz skupine: vezi do Ln, C-j-Cio alkila 52 52 substituiranega z 0-3 R , arila substituiranega z 0-3 R , cikioalkila 52 52 substituiranega z 0-3 R , heterocikla substituiranega z 0-3 R , heterocikloalkila 52 52 substituiranega z 0-3 R , aralkila substituiranega z 0-3 R in alkarila 52 substituiranega z 0-3 R ; 41 52 R je neodvisno izbran iz skupine: vodika, arila substituiranega z 0-3 R , C^-Cio 52 52 alkila substituiranega z 0-3 R , in heterocikla substituiranega z 0-3 R ; 52 R je ob vsakem pojavu neodvisno izbran iz skupine: vezi do Ln, =0, F, Cl, Br, J, -CF3, -CN, -C02R53, -C(=0)R53, -C(=0)N(R53)2i -CHO, -ch2or53, -0C(=0)R53, -0C(=0)0R53a, -OR53, -0C(=0)N(R53)2, -NR53C(=0)R53, -NR54C(=0)0R53a, -NR53C(=0)N(R53)2, -NR54S02N(R53)2, -NR54S02R53a, -S03H, -S02R53a, -SR53, -S(=0)R53a, -S02N(R53)2, -N(R53)2, -NHC(=NH)NHR53, -C(=NH)NHR53, =nor53, no2, co cqa -C(=0)NH0R , -C(=0)NHNRR , -0CH2C02H, 2-(1-morfolino)etoksi; 53 _53a 54 R , R , m R so vsak, ob vsakem pojavu, neodvisno izbrani iz skupine: vodika, 0·|-0β alkila, in vezi do L^; 80 81 85 R in R sta neodvisno izbrana iz skupine: H; 0^-0^q alkila; -CN; -C02R ; oc ec λa -C(=0)R ;-C(=0)N(R )2; C2-Cio 1-alkena substituiranega z 0-3 R ; C2-Ciq 84 84 1 -alkina substituiranega z 0-3 R ; arila substituiranega z 0-3 R ; nenasičenega 84 heterocikla substituiranega z 0-3 R ; in nenasičenega karbocikla 84 80 81 substituiranega z 0-3 R ; pod pogojem, da ko je eden od R in R H ali alkil, potem drugi ni H ali alkil; 80 81 ali, alternativno, R in R sta lahko združena s prikazanim dvovalentnim ogljikovim radikalom, da se tvori: -4-
    η pri čemer: 02 00 04 R in R sta lahko neodvisno izbrana iz skupine: H; R ; C-j-C-io alkila 84 84 substituiranega z 0-3 R ; C2-C10 alkenila substituiranega z 0-3 R ; C2- C10 alkinila substituiranega z 0-3 R84; arila substituiranega z 0-3 R84; 84 heterocikla substituiranega z 0-3 R ; in karbocikla substituiranega z 0-3 R84; 82 83 ali, alternativno, R , R sta lahko združena, da se tvori združen aromatski ali heterociklični obroč; a in b kažeta položaja opcijskih dvojnih vezi in n je 0 ali 1, 84 R je ob vsakem pojavu neodvisno izbran iz skupine: =0, F, Cl, Br, J, -CF3, -CN, -CO2R85, -C(=0)R85, -C(=0)N(R85)2, -N(R85)3+, -CH2OR85, -0C(=0)R85, -0C(=0)0R85a, -OR85, -0C(=0)N(R85)2, -NR85C(=0)R85, -NR86C(=0)0R85a, -NR85C(=0)N(R85)2, -NR86S02N(R85)2, -NR86S02R85a, -SO3H, -S03Na, -S02R85a, -SR85, -SisOJR853, -S02N(R85)2, -N(R85)2, -NHC(=NH)NHR85, -C(=NH)NHR85, =NOR85, -C(=0)NH0R85, -0CH2C02H, 2-(1-morfolino)etoksi; in R85, R853, in R86 so vsak, ob vsakem pojavu, neodvisno izbrani iz skupine: vodika, C-t-Cg alkila.
  2. 2. Reagent po zahtevku 1, pri čemer: -5- Q je biološko aktivna molekula, izbrana iz skupine: llb/llla receptorskih antagonistov, llb/llla receptorskih ligandov, peptidov, ki vežejo fibrin, peptidov, ki vežejo levkocite, kemotaktičnih peptidov, somatostatinskih analogov, in peptidov, ki vežejo selektin; d’ je 1 do
  3. 3; Ln je: pri čemer: 9" je 0-5; f je 0-5; f je 1-5; 1 p 56 Y in y sta ob vsakem pojavu neodvisno izbrana iz: O, NR , C=0, C(=0)0, 56 0C(=0)0, C(=0)NH-, C=NR , S, SO, S02, S03, NHC(=0), (NH)2C(=0), (NH)2C=S; 55 56 R in R sta ob vsakem pojavu neodvisno izbrana iz: vodika, CfC^o alkila, in alkarila; Hz je stabilen hidrazon s formulo: R80 / N=C R40^' R81 R41 -6- pri čemer, 40 R je ob vsakem pojavu neodvisno ozbran iz skupine: arila substituiranega z 0-3 52 52 R , in heterocikla substituiranega z 0-3 R ; 41 52 R je neodvisno izbran iz skupine: vodika, arila substituiranega z 0-1 R , C-1-C3 52 52 alkila substituiranega z 0-1 R , in heterocikla substituiranega z 0-1 R ; 52 53 R je ob vsakem pojavu neodvisno izbran iz skupine: vezi do Ln, -CO2R , -CH2OR53, -S03H, -S02R53a, -N(R53)2, -NHC(=NH)NHR53, in -0CH2C02H; 53 53a R , R sta vsak, ob vsakem pojavu, neodvisno izbrana iz skupine: vodika in C1-C3 alkila; 80 85 R je ob vsakem pojavu neodvisno izbran iz skupine: -C02R ; C2-C5 1-alkena 84 84 substituiranega z 0-3 R ; C2-Cs 1-alkina substituiranega z 0-3 R ; arila 84 84 substituiranega z 0-3 R ; nenasičenega heterocikla substituiranega z 0-3 R ; 81 R je ob vsakem pojavu neodvisno izbran iz skupine: H in C-| -C5 alkila; 80 81 ali, alternativno, R in R , ko sta združena s prikazanim dvovalentnim ogljikovim radikalom tvorita
    n 82 83 84 pri Čemer sta R in R lahko neodvisno izbrana iz skupine: H in R ; -7- 82 83 ali, alternativno, R , R sta lahko združena, da se tvori združen aromatski ali heterociklični obroč; a in b kažeta položaja opcijskih dvojnih vezi in n je 0 ali 1, 84 85 R je ob vsakem pojavu neodvisno izbran iz skupine: -C02R , ~C(=0)N(R85)2, -CH2OR85, -0C(=0)R85, -OR85, -SO3H, -N(R85)2, -0CH2C02H; ge R je ob vsakem pojavu neodvisno izbran iz skupine: vodika, C1-C3 alkila. 3. Reagent po zahtevku 2, pri čemer: Q predstavlja biološko aktivno molekulo, izbrano iz skupine: llb/llla receptorskih antagonistov in kemotaktičnih peptidov; d’ je 1; L-n je: -(CR55R58)g"-[Y1 (CR55R56)fY2]f'-(CR55R56)g·-, pri čemer: g" je 0-5; f je 0-5; f je 1-5; Y1 in Υ2 sta ob vsakem pojavu neodvisno izbrana iz: O, NR56, C=0, C(=0)0, 0C(=0)0, C(=0)NH-, C=NR56, S, NHC(=0), (NH)2C(=0), (NH)2C=S; -8- „55. „56 . ... R in R sta vodik; Hz je stabilen hidrazon s formulo: R80 N=c R40·»/ R81 R41 pri čemer, 40 R je ob vsakem pojavu neodvisno izbran iz skupine: heterocikla 52 substituiranega z R ; R41 je vodik; 52 R je vez do L*,; 80 85 R je neodvisno izbran iz skupine: -CO2R ; C2-C3 1-alkena substituiranega z 84 84 0-1 R ; arila substituiranega z 0-1 R ; nenasičenega heterocikla 84 substituiranega z 0-1 R ; R81jeH; 84 85 85 R je ob vsakem pojavu neodvisno izbran iz skupine: -CO2R ; -OR ; -SO3H; -N(R85)2; 85 R je ob vsakem pojavu neodvisno izbran iz skupine: H in metila.
  4. 4. Reagent po zahtevku 3, pri čemer je Q ciklični llb/llla receptorski antagonist. -9-
  5. 5. Reagenti po zahtevku 4, ki so
    -10-
    -11-ΝΗ
    -12-
    -13-
    ΝΗ
    -14- ΝΗ
    OCH3
  6. 6. Komplet za pripravo radiofarmacevtika, ki obsega: (a) vnaprej določeno količino sterilnega, farmacevtsko sprejemljivega reagenta po kateremkoli od zahtevkov 1-3 in 4; (b) vnaprej določeno količino enega ali več sterilnih, farmacevtsko sprejemljivih pomožnih ligandov; (c) vnaprej določeno količino sterilnega, farmacevtsko sprejemljivega reducenta, in (d) opcijsko, vnaprej določeno količino sterilne, farmacevtsko sprejemljive komponente, izbrane iz skupine: prenašalnih ligandov, pufrov, liofilizacijskih sredstev, stabilizacijskih sredstev, sredstev za raztapljanje in bakteriostatikov.
  7. 7. Komplet za pripravo radiofarmacevtikov, ki obsega: -15- (a) vnaprej določeno količino sterilnega, farmacevtsko sprejemljivega reagenta po kateremkoli od zahtevkov 1 -3 in 4; (b) vnaprej določeno količino dveh sterilnih, farmacevtsko sprejemljivih pomožnih ligandov; (c) vnaprej določeno količino sterilnega, farmacevtsko sprejemljivega reducenta; in (d) opcijsko, vnaprej določeno količino sterilne, farmacevtsko sprejemljive komponente, izbrane iz skupine: prenašalnih ligandov, pufrov, liofilizacijskih sredstev, stabilizacijskih sredstev, sredstev za raztapljanje in bakteriostatikov.
SI9620076A 1995-06-07 1996-06-07 Stabilni reagenti za pripravo radiofarmacevtikov SI9620076B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/476,296 US5750088A (en) 1993-03-30 1995-06-07 Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
PCT/US1996/009766 WO1996040637A1 (en) 1995-06-07 1996-06-07 Stable reagents for the preparation of radiopharmaceuticals

Publications (2)

Publication Number Publication Date
SI9620076A SI9620076A (sl) 1998-08-31
SI9620076B true SI9620076B (sl) 2000-02-29

Family

ID=23891282

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9620076A SI9620076B (sl) 1995-06-07 1996-06-07 Stabilni reagenti za pripravo radiofarmacevtikov

Country Status (29)

Country Link
US (2) US5750088A (sl)
EP (1) EP0832068B1 (sl)
JP (1) JPH11507364A (sl)
KR (1) KR19990022573A (sl)
CN (1) CN1192733A (sl)
AR (1) AR003959A1 (sl)
AT (1) ATE233241T1 (sl)
AU (1) AU718683B2 (sl)
BR (1) BR9609003A (sl)
CA (1) CA2222183A1 (sl)
CZ (1) CZ380197A3 (sl)
DE (1) DE69626392T2 (sl)
EA (1) EA000742B1 (sl)
EE (1) EE9700313A (sl)
ES (1) ES2193245T3 (sl)
HR (1) HRP960250A2 (sl)
HU (1) HUP9901469A3 (sl)
IL (1) IL118468A0 (sl)
LT (1) LT4380B (sl)
LV (1) LV12044B (sl)
MX (1) MX9709126A (sl)
MY (1) MY133974A (sl)
NO (1) NO975678L (sl)
NZ (1) NZ310799A (sl)
PL (1) PL323995A1 (sl)
SI (1) SI9620076B (sl)
SK (1) SK163497A3 (sl)
WO (1) WO1996040637A1 (sl)
ZA (1) ZA964854B (sl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0888130B1 (en) * 1996-03-13 2003-07-02 Bristol-Myers Squibb Pharma Company New ternary radiopharmaceutical complexes
WO1998015295A2 (en) * 1996-10-07 1998-04-16 Dupont Pharmaceuticals Company Radiopharmaceuticals for imaging infection and inflammation
US6416733B1 (en) * 1996-10-07 2002-07-09 Bristol-Myers Squibb Pharma Company Radiopharmaceuticals for imaging infection and inflammation
US20030124053A1 (en) * 1996-10-07 2003-07-03 Barrett John Andrew Radiopharmaceuticals for imaging infection and inflammation
US6403054B1 (en) * 1997-05-28 2002-06-11 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
CA2326978A1 (en) * 1998-04-03 1999-10-14 Milind Rajopadhye Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer
HRP990317A2 (en) * 1998-10-13 2000-06-30 Du Pont Pharm Co A process for the preparation of a thrombus imaging agent
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
TR200101757T2 (tr) * 1998-12-18 2001-12-21 Dupont Pharmaceuticais Company Vitronektin reseptör antagonisti farmasötikler
JP2002532440A (ja) 1998-12-18 2002-10-02 デュポン ファーマシューティカルズ カンパニー ビトロネクチン受容体拮抗剤薬剤
US6794518B1 (en) * 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2000057787A2 (en) * 1999-03-26 2000-10-05 Du Pont Pharmaceuticals Company Method for localization of blood clots
US6808698B1 (en) 1999-03-26 2004-10-26 Bristol-Myers Squibb Pharma Company Method for localization of blood clots
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US20030220646A1 (en) * 2002-05-23 2003-11-27 Thelen Sarah L. Method and apparatus for reducing femoral fractures
US6534038B2 (en) 2000-04-07 2003-03-18 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
JP2004512382A (ja) 2000-11-03 2004-04-22 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 心臓灌流および心臓炎症の２核種同時イメージング
GB0031592D0 (en) * 2000-12-28 2001-02-07 Nycomed Amersham Plc Stabilised radiopharmaceutical compositions
CA2452478A1 (en) * 2001-08-08 2003-02-20 Bristol-Myers Squibb Pharma Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US6838074B2 (en) 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7317104B2 (en) 2003-06-13 2008-01-08 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7319149B2 (en) * 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
CN100418585C (zh) * 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
KR20080022588A (ko) * 2005-06-30 2008-03-11 브리스톨-마이어스 스퀴브 파마 컴퍼니 영상화제로서의 히드라지드 컨쥬게이트
JPWO2007046411A1 (ja) * 2005-10-19 2009-04-23 大日本住友製薬株式会社 イソキサゾール化合物の安定化方法
KR20080080206A (ko) * 2005-12-20 2008-09-02 아스트라제네카 아베 Ｇａｂａａ-수용체 조절제로서의 치환된 신놀린 유도체 및그의 합성 방법
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
JP5571387B2 (ja) 2007-01-11 2014-08-13 クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド 癌の治療のための化合物および方法
TW200911760A (en) * 2007-06-19 2009-03-16 Astrazeneca Ab Compounds and uses thereof
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CA2730890C (en) * 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
KR101630475B1 (ko) 2008-12-29 2016-06-14 사노피 ２-피리딘-２-일-피라졸-３（２ｈ）-온의 유도체, 그의 제조법 및 치료 용도
BRPI0924060A8 (pt) 2008-12-29 2015-09-29 Sanofi Sa derivados de 2-piridin-2-il-pirazol-3(2h)-ona, o respectivo preparo e a respectiva aplicação em terapêutica com ativadores de hif
FR2949468B1 (fr) * 2009-08-28 2011-09-30 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
FR2940652B1 (fr) * 2008-12-29 2011-02-11 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
FR2967671A1 (fr) * 2010-11-24 2012-05-25 Pf Medicament Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
CN110818624B (zh) * 2019-11-22 2022-11-22 华东理工大学 吡啶季铵盐腙类化合物及制备方法与在抗菌或香料缓释中的应用
CN112999369B (zh) * 2021-03-03 2022-02-25 江苏元本生物科技有限公司 一种her2亲合体放射性核素标记物组合物及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
CA1300608C (en) * 1985-05-10 1992-05-12 Edward A. Deutsch 99 mtc (iii) myocardial imaging agents which are non-reducable in vivo
GB8624272D0 (en) * 1986-10-09 1986-11-12 Amersham Int Plc Cationic complexes of tc-99m
US5217705A (en) 1987-09-25 1993-06-08 Neorx Corporation Method of diagnosing blood clots using fibrin-binding proteins
DE3855458T2 (de) 1987-12-10 1996-12-05 Jolla Cancer Res Found Verfahren zur herstellung von conformationnell stabilisierten zelladhäsionspeptiden
US5300278A (en) * 1988-03-09 1994-04-05 Cis Bio International Process for the preparation of 99m Tc, 186 Re or 188 Re nitride complexes usable as radiopharmaceutical products
GB8808414D0 (en) * 1988-04-11 1988-05-11 Amersham Int Plc Ligands & cationic complexes thereof with technetium-99m
JPH03505087A (ja) 1988-04-29 1991-11-07 ニュー　イングランド　ディーコネス　ホスピタル　コーポレイション ハイブリッドペプチド及びその使用方法
US5002754A (en) * 1988-06-15 1991-03-26 University Of Cincinnati Technetium (III/II) imaging agents
WO1990003391A1 (en) 1988-09-29 1990-04-05 Biogen, Inc. Hirudin peptides
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5270030A (en) 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
GB8902362D0 (en) * 1989-02-03 1989-03-22 Amersham Int Plc Cationic complexes of technetium-99m
IL93432A (en) * 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US5206370A (en) * 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
US4957728A (en) * 1989-05-19 1990-09-18 University Of Cincinnati Kit for preparing Tc (III)-99m myocardial imaging agents that are effective in humans
US4917879A (en) * 1989-05-19 1990-04-17 University Of Cincinnati 99MTC(III) myocardial imaging agents that are effective in humans
GB8914020D0 (en) 1989-06-19 1989-08-09 Antisoma Ltd Synthetic peptides for use in thrombus detection
EP0410537A1 (en) 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
GB8919488D0 (en) * 1989-08-29 1989-10-11 Amersham Int Plc New cores for technetium radiopharmaceuticals
ZA907743B (en) 1989-10-03 1991-07-31 Merrell Dow Pharma Radiolabeled anticoagulant peptides
US5086069A (en) 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
FR2664166A1 (fr) * 1990-07-04 1992-01-10 Cis Bio Int Procede de preparation de complexes nitruro de metaux de transition utilisables comme produits radiopharmaceutiques ou pour la synthese de nouveaux produits radiopharmaceutiques.
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
AU8730691A (en) * 1990-09-28 1992-04-28 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5112594A (en) * 1991-04-04 1992-05-12 Mallinckrodt Medical, Inc. Kit for preparing a technetium-99m myocardial imaging agent
CA2101942C (en) 1991-02-08 2001-01-30 Richard T. Dean Technetium-99m labeled polypeptides for imaging
FR2679452B1 (fr) * 1991-07-22 1993-11-12 Cis Bio International Produit radiopharmaceutique ayant notamment un tropisme cerebral, comportant un complexe nitruro d'un metal de transition, et son procede de preparation.
US5362852A (en) * 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
DK0641222T3 (da) 1992-05-21 2000-12-11 Diatide Inc Peptider mærket med technetium-99m til trombeafbildning
GB2268494B (en) 1992-07-08 1996-08-21 Kenneth Francis Prendergast Imaging compositions
FR2698272B1 (fr) * 1992-11-20 1994-12-30 Cis Bio Int Procédé de marquage cellulaire au moyen de complexes nitruro-bis (dithiocarbamato)Tc-99m et trousse pour la mise en Óoeuvre de ce procédé.
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders

Also Published As

Publication number Publication date
LT4380B (lt) 1998-09-25
PL323995A1 (en) 1998-04-27
IL118468A0 (en) 1996-09-12
LV12044A (lv) 1998-05-20
HUP9901469A3 (en) 2000-02-28
DE69626392D1 (de) 2003-04-03
ZA964854B (en) 1997-12-08
BR9609003A (pt) 1999-12-14
NZ310799A (en) 2000-01-28
EA000742B1 (ru) 2000-02-28
HRP960250A2 (en) 1997-12-31
JPH11507364A (ja) 1999-06-29
CA2222183A1 (en) 1996-12-19
CZ380197A3 (cs) 1998-07-15
CN1192733A (zh) 1998-09-09
MY133974A (en) 2007-11-30
WO1996040637A1 (en) 1996-12-19
LT97191A (en) 1998-04-27
AU6166196A (en) 1996-12-30
EA199800025A1 (ru) 1998-06-25
ES2193245T3 (es) 2003-11-01
MX9709126A (es) 1998-03-31
HUP9901469A2 (hu) 1999-08-30
SK163497A3 (en) 1998-10-07
KR19990022573A (ko) 1999-03-25
DE69626392T2 (de) 2004-04-22
US5750088A (en) 1998-05-12
EP0832068B1 (en) 2003-02-26
SI9620076A (sl) 1998-08-31
NO975678D0 (no) 1997-12-05
ATE233241T1 (de) 2003-03-15
LV12044B (en) 1998-09-20
AR003959A1 (es) 1998-09-30
NO975678L (no) 1998-02-06
AU718683B2 (en) 2000-04-20
US6015904A (en) 2000-01-18
EE9700313A (et) 1998-06-15
EP0832068A1 (en) 1998-04-01

Similar Documents

Publication Publication Date Title
SI9620076B (sl) Stabilni reagenti za pripravo radiofarmacevtikov
SI9620044B (sl) Ternarni radiofarmacevtski kompleksi
EP3397968B1 (en) Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy
US11478558B2 (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
RU2464272C2 (ru) Арилфосфорамидаты нуклеозида и их применение в качестве противовирусных средств для лечения вирусного гепатита с
ES2972148T3 (es) Agentes de alta afinidad dirigidos a antígenos de membrana específicos de próstata para la endorradioterapia del cáncer de próstata
ES2338414T3 (es) Agentes y metodos de diagnostico por imagen de naaladasa y psma.
JP2004529884A5 (sl)
PT87802B (pt) Processo para a preparacao de complexos de rodio com quelantes de poliamina funcionalizada
EP3973998B1 (en) Methods for cell labeling and medical imaging
CA3137963A1 (en) Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents
WO2022189304A2 (en) Aliphatic 18f-radiolabeling of a tetrazine precursor
ES2654528T3 (es) Procedimiento de preparación de un derivado de purina marcado, dicho derivado y sus usos
CN103732563B (zh) 18f-糖-叶酸类
US20080260636A1 (en) Stabilization of radionuclide-containing compositions
ES2985919T3 (es) Agentes diagnósticos y terapéuticos dirigidos a CXCR4 con selectividad de especie reducida
CA3149598A1 (en) Novel theranostic agents for psma positive cancers
US20170274087A1 (en) Saccharide analogs and agents for the diagnosis and therapy of bacterial infections
JP4723378B2 (ja) 石灰化組織親和性化合物
KR102548998B1 (ko) 혈전영상을 위한 방사성의약품 및 조성물
WO2017076879A1 (en) [18f] radiotracers and their uses
ES2685289T3 (es) Método de radioyodación
JP2014511338A (ja) 放射性ヨウ素化グアニジン
KR20060100200A (ko) 방사선제약 화합물의 합성에 유용한 보조기
NZ792994A (en) Psma combiner and use thereof